A5068920217- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Adrenal Hormones and Disorders
- Growth Hormone and Insulin-like Growth Factors
- Hormonal Regulation and Hypertension
- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Cancer, Hypoxia, and Metabolism
- Neuroendocrine Tumor Research Advances
- Stress Responses and Cortisol
- Diabetes Management and Research
- Cardiac, Anesthesia and Surgical Outcomes
- Cerebral Venous Sinus Thrombosis
- Diabetes Treatment and Management
- Thyroid Cancer Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- Sexual Differentiation and Disorders
- Myasthenia Gravis and Thymoma
- Traumatic Brain Injury and Neurovascular Disturbances
- Diabetes and associated disorders
- Mitochondrial Function and Pathology
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Head and Neck Surgical Oncology
- Peripheral Neuropathies and Disorders
- Sinusitis and nasal conditions
Johns Hopkins University
2018-2025
Johns Hopkins Medicine
2020-2025
Johns Hopkins Hospital
2019-2020
Cleveland Clinic
2007-2017
Abu Dhabi Health Services
2017
Diabetes Australia
2010-2014
Max Planck Institute for Metabolism Research
2012
Cleveland Clinic Lerner College of Medicine
2008
Case Western Reserve University
1999-2004
University Hospitals of Cleveland
2004
Because more than 90 percent of circulating cortisol in human serum is protein-bound, changes the binding proteins can alter measured total concentrations without influencing free this hormone. We investigated effect decreased amounts cortisol-binding on and during critical illness, when glucocorticoid secretion maximally stimulated.Base-line cortisol, cosyntropin-stimulated aldosterone, were 66 critically ill patients 33 healthy volunteers groups that similar with regard to sex age. Of...
Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure high cortisol concentrations. Our objective was evaluate the safety efficacy of mifepristone, glucocorticoid receptor antagonist, in endogenous CS. We conducted 24-wk multicenter, open-label trial after failed multimodality therapy at 14 U.S. academic medical centers three private research centers. Participants included 50 adults CS type 2 diabetes mellitus/impaired glucose...
The clinical features and increased mortality associated with Cushing's syndrome result from a chronic excess of circulating cortisol. As LCI699 potently inhibits 11β-hydroxylase, which catalyzes the final step cortisol synthesis, it is potential new treatment for disease, most common cause endogenous syndrome.Adult patients moderate-to-severe disease (urinary free [UFC] levels >1.5 × ULN [upper limit normal]) received oral 10 weeks in this proof-of-concept study. was initiated at 4 mg/d two...
In a 10-week proof-of-concept study (LINC 1), the potent oral 11β-hydroxylase inhibitor osilodrostat (LCI699) normalized urinary free cortisol (UFC) in 11/12 patients with Cushing's disease. The current 22-week 2; NCT01331239) further evaluated Phase II, open-label, prospective of two patient cohorts. Follow-up cohort: 4/12 previously enrolled LINC 1, offered re-enrollment if baseline mean UFC was above ULN. Expansion 15 newly > 1.5 × follow-up cohort, initiated twice daily at penultimate...
Accurate assessment of the hypothalamic-pituitary-adrenal (HPA) axis is critical for appropriate management disease in patients with pituitary adenoma after transsphenoidal resection. The authors examine role morning total serum cortisol level early postoperative period as a predictor long-term HPA function.Morning was measured 83 on Day 1 (or 2 if patient received glucocorticoids during surgery) surgery adenoma. These results were compared those definitive assays function performed at 1-3...